v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information

Note 10 - Segment Information

 

The Company has identified two operating segments, diagnostic services and consumer products, based on the manner in which the Company’s CEO, as Chief Operating Decision Maker, assesses performance and allocates resources across the organization. The operating segments are organized in a manner that depicts the difference in revenue generating synergies that include the separate processes, profit generation and growth of each segment. The diagnostic services segment provides diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. The unallocated corporate expenses mainly included professional fees associated with the public company.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table is a summary of segment information for three and six months ended June 30, 2026 and 2025 (amounts in thousands):

 

   June 30, 2026   June 30, 2025   June 30, 2026   June 30, 2025 
   For the three months ended   For the six months ended 
   June 30, 2026   June 30, 2025   June 30, 2026   June 30, 2025 
Net revenues                    
Diagnostic services  $-   $-   $-   $- 
Consumer products   1,011    1,247    2,180    2,678 
Consolidated net revenue   1,011    1,247    2,180    2,678 
Cost of revenue                    
Diagnostic services   -    112    -    344 
Consumer products   785    401    1,659    1,074 
Consolidated cost of revenue   785    513    1,659    1,418 
Depreciation and amortization expense                    
Diagnostic services   -    205    -    539 
Consumer products   623    805    1,245    1,612 
Total Depreciation and amortization expense   623    1,010    1,245    2,151 
Operating and other expenses        -         - 
Diagnostic services   -    1,560    -    1,728 
Consumer products   760    211    1,271    1,272 
Unallocated corporate   1,882    1,646    4,845    4,480 
Total operating and other expenses   2,642    3,417    6,116    7,480 
Income (loss) from operations, before income taxes                    
Diagnostic services   -    (1,877)   -    (2,611)
Consumer products   (1,157)   (170)   (1,995)   (1,280)
Unallocated corporate   (1,882)   (1,646)   (4,845)   (4,480)
Total loss from operations, before income taxes   (3,039)   (3,693)   (6,840)   (8,371)
Income tax expense   (12)   (779)   (1,386)   (779)
Total loss from operations, after income taxes   (3,051)   (4,472)   (8,226)   (9,150)
Net loss from continuing operations  $(3,051)  $(4,472)  $(8,226)  $(9,150)

 

The following table is a summary of segment information as of June 30, 2026 and December 31, 2025 (amounts in thousands):

 

   June 30,   December 31, 
   2026   2025 
ASSETS          
Consumer products  $10,309   $11,614 
Unallocated corporate   47,100    48,257 
Total assets  $57,409   $59,871